During the early trading session on October 31, key Hong Kong stock indices adjusted, with the Hang Seng Tech Index falling over 1% at one point. In contrast, the Hang Seng Biotechnology Index, which focuses on the innovative drug industry chain, rose against the trend, gaining nearly 2% intraday. The largest ETF tracking this index, the Hang Seng Healthcare ETF (159892), surged over 2%, led by companies such as 3SBio, Innovent Biologics, and Duality Biologics.

The Hang Seng Biotechnology Index was launched by Hang Seng Indexes Company in 2019 to reflect the overall performance of the biotechnology sector in the Hong Kong stock market. Compared to indices highly focused on innovative drugs, the Hang Seng Biotechnology Index also includes upstream CXO, enabling it to more accurately capture the performance of the entire innovative drug industry chain.

Additionally, the Hong Kong Exchange announced on October 14 its plan to launch futures for the Hang Seng Biotechnology Index, further optimizing its expanding derivatives ecosystem. The new futures contract will begin trading on November 28, 2025, providing investors with a precise risk management tool. The Hang Seng Biotechnology Index futures are also the only index futures available for the healthcare and medical sectors in the Hong Kong stock market.

Founder Securities stated that the industry's prosperity is entering a new upward cycle, with overseas orders accelerating and still in the early stages of industry growth. The upward momentum is strong, and they firmly看好 upstream biotechnology companies with strong overseas expansion capabilities. Within the CXO sector, the early R&D industry chain has significant development potential, and innovative drug出海 presents a historic opportunity.